Agenus

We will report Q1 2026 financial results before market open on Mon, May 11. A June webcast, held with our Annual Meeting of Shareholders, will spotlight strategic priorities, data milestones and progress across the global BOT/BAL program. Read Release: bit.ly/3KSL3Qw

Agenus is heading to #ASCO2026 with 4 accepted abstracts, including the first Phase 2 presentation of #BOT+/-BAL in advanced cutaneous #melanoma, plus #CRC and translational research updates. Read press release: bit.ly/3KSL3Qw $AGEN #immunotherapy #biotech

Agenus and BAP Pharma announced an exclusive global partnership supporting authorized access programs for investigational BOT+BAL, including France’s AAC pathway and named-patient programs in select countries. Read release:bit.ly/3KSL3Qw

Our updated April 2026 corporate overview is now available, highlighting BOT+BAL #CRC progress, Phase 3 BATTMAN rationale, expansion potential, and key 2026 catalysts. Visit our IR site: bit.ly/4mu15Po View the deck: bit.ly/4cmW5HO $AGEN #Immunotherapy

MiNK is live in Los Angeles for #AACRIO25. Tune in later today to hear new translational data from the ongoing Ph2 study evaluating allo-iNKTs (agenT-797) in combination with @Agenus_Bio's BOT/BAL & chemotherapy in refractory #GastricCancer. Learn more: bit.ly/3XhoXKS

MiNK Therapeutics announces abstract acceptance at American Thoracic Society (ATS) International Conference 2026 Featuring #agenT-797 in a novel combo approach for persistent infection—highlighting the potential of iNKT cell therapy beyond oncology.📍 Poster #103 | May 20 Details: bit.ly/47tm7bb #ATS2026 #Immunotherapy #CellTherapy

Agenus announces data from a Phase II investigator sponsored trial of #BOT/BAL + @MiNK_iNKT agenT-797 in PD-1 refractory gastroesophageal cancer. 🔹Apr 20 🔹2–5 PM PT 🔹Poster 52 | CT166 #AACR25 #Immunotherapy #Oncology

First patient enrolled in our global Phase 3 #BATTMAN trial evaluating #BOT+BAL in MSS/pMMR mCRC — a population historically resistant to immunotherapy. A key step forward as we advance our registrational program. 🔗bit.ly/3KSL3Qw #Oncology #Immunotherapy $AGEN

We’re live. Join now for updates on #BOT+BAL, #access programs, and 2026 priorities. ▶️ Watch: vimeo.com/event/5828543 #immunotherapy #CRC #innovation

Reminder: Join our March Stakeholder Webcast today. Updates on #BOT+BAL, global #access, and 2026 priorities. Register: vimeo.com/event/5828543 Submit Questions: app.sli.do/event/qBiptRwc…

March is Colorectal Cancer Awareness Month. But for patients, the need for better options doesn’t end on March 31. Our focus continues on advancing #immunotherapy for those with the fewest options. #CRCAwarenessMonth #innovation

Agenus announces March webcast on Tues, Mar 31st at 4:30EST Updates on: • Clinical progress • Global access (France AAC + NPP) • 2026 priorities Live Q&A included. Register: vimeo.com/event/5828543 Submit questions: app.sli.do/event/qBiptRwc… #Immunotherapy #Oncology #BOT

At Agenus, we believe innovation should confront tumors historically resistant to #immunotherapy and real progress means moving beyond incremental benefit. #CRCAwarenessMonth #UnmetNeed #Innovation

Every cancer treatment available today began in a clinical trial. Patients who participate in research help bring tomorrow’s treatments to patients today. #CRCAwarenessMonth #ClinicalTrials

CRC is rising in younger adults. Know the warning signs. Awareness can save lives. #CRCAwarenessMonth #CRC #signs

27,000 blue flags on the National Mall. Each represents a life that may be lost to #CRC in 2030-- unless we ACT NOW. Thank you to @FightCRC for honoring these lives and raising awareness of a disease that is now the leading cause of cancer death in people under 50 in the U.S.

At #AACR2026, prelim results from the investigator-sponsored #BBOpCo study led by Nicholas DeVito from Duke, will be presented evaluating #BOT+BAL in 1L MSS #CRC. A shift toward using IO earlier to potentially reduce reliance on chemo + surgery. Release: bit.ly/3KSL3Qw

Innovation only matters if patients can access it. We remain committed to expanding responsible global access pathways while advancing registrational trials. Because time matters. #CRCAwarenessMonth #AccessToInnovation

Innovation in cancer care cannot be incremental. Agenus continues to build clinical evidence for #BOT + BAL, while physician and patient interest grows globally. In parallel, we are strengthening manufacturing to support expanding clinical and access programs. #immunotherapy

Agenus reports 2025 results and progress for BOT+BAL • P3 BATTMAN trial underway in MSS mCRC • 42% 2-year OS in heavily pretreated pts • 200+ HCP access inquiries from 30+ countries • $4.2M initial revenue from access programs bit.ly/3KSL3Qw